Mark Feitelson

Temple University

Mark Feitelson received his Ph.D. in Microbiology and Immunology from UCLA in 1979. He began his work on the pathogenesis of chronic hepatitis B at Stanford University and was then recruited to the Fox Chase Cancer Center by Nobel laureate Dr. Baruch Blumberg. In 1991, Dr. Feitelson moved to Thomas Jefferson University where he became a Professor of Pathology and Cell Biology and director of the Molecular Diagnostics Lab in Microbiology. In 2007, Dr. Feitelson was appointed Professor of Biology at Temple University. He is also the CSO of SFA Therapeutics. His work has been supported by NIH, industry and foundations, and he has mentored over 130 students. He has more than 150 publications, 180 abstracts and 11 patents.

Mark Feitelson

1books edited

1chapters authored

Latest work with IntechOpen by Mark Feitelson

Hepatocellular carcinoma (HCC) is a common tumor type arising from several distinct etiologies. It is usually diagnosed late and is difficult to treat. This volume presents an overview of selected aspects of HCC pathogenesis, and research aimed at developing diagnostic biomarkers. It points to a number of putative therapeutic targets, including signal transduction pathways, metabolic and epigenetic alterations in tumor cells, the tumor microenvironment, the gut microbiome, and functions of immune effector cells. Given the multi-step nature of most cancers, including HCC, future drug development will most likely require combination therapies that will simultaneously target multiple steps in hepatocarcinogenesis.

Go to the book
Liver Cancer IntechOpen
Liver Cancer Genesis, Progression and Metastasis Edited by Mark Feitelson

Liver Cancer

Edited by Mark Feitelson